950746-21-1

Basic information

• Product Name: 6,8-dichloro-2,7-naphthyridin-1-ol
• Synonyms: 6,8-dichloro-2,7-naphthyridin-1-ol;6,8-Dichloro-1-hydroxy-2,7-naphthyridine;6,8-Dichloro-2,7-naphthyridine-1(2H)-one;6,8-Dichloro-2,7-naphthyridin-1(2H)-one;6,8-Dichloro-2,7-naphthyridin-1(2H)
• CAS NO: 950746-21-1
• Molecular Formula: C₈H₄Cl₂N₂O
• Molecular Weight: 215.03616
• Product Categories: Non-Chiral heterocyclic compounds
• Mol File: 950746-21-1.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Density: 1.544
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6,8-dichloro-2,7-naphthyridin-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 6,8-dichloro-2,7-naphthyridin-1-ol(950746-21-1)
• EPA Substance Registry System: 6,8-dichloro-2,7-naphthyridin-1-ol(950746-21-1)

Safety Data

• Hazardous Substances Data: 950746-21-1(Hazardous Substances Data)

Usage

General Description

6,8-dichloro-2,7-naphthyridin-1-ol is a chemical compound with the molecular formula C9H5Cl2NO. It is a chlorinated naphthyridine derivative with a hydroxyl group attached to the 1-position of the heterocyclic ring. 6,8-dichloro-2,7-naphthyridin-1-ol has potential biological and pharmaceutical applications due to its unique structure and properties. It may be used as a building block in the synthesis of various organic and medicinal compounds, as well as in research and development of new drugs and materials. Additionally, the chlorinated naphthyridine structure may also confer certain biological activities, making it of interest for further study in the field of pharmacology and biochemistry. Overall, 6,8-dichloro-2,7-naphthyridin-1-ol is a versatile and potentially valuable chemical compound with a range of possible applications in various fields of science and industry.

Upstream product

• 950746-20-0 2,6-dichloro-4-(2-(pyrrolidin-1-yl)vinyl)nicotinonitrile 
• 1175559-53-1 2,6-dichloro-4-[(E)-2-(dimethylamino)ethenyl]pyridine-3-carbonitrile 
• 5444-02-0 2,6-dihydroxy-3-cyano-4-methylpyrimidine 
• 875-35-4 2,6-dichloro-4-methylnicotinonitrile 

Downstream Products

• 1175559-54-2 (R)-6-chloro-8-(3-methyl-4-(2-methylmorpholino)phenylamino)-2,7-naphthyridin-1(2H)-one hydrochloride 
• 1391001-23-2 6-chloro-8-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2,7-naphthyridin-1(2H)-one 
• 1391001-03-8 6-(2,6-dichlorobenzyl)-8-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-2,7-naphthyridin-1(2H)-one trifluoroacetate 
• 1391418-83-9 6-(2-chloro-6-fluorobenzyl)-8-[4-(piperazin-1-yl)phenyl]amino-2,7-naphthyridin-1(2H)-one 
• 1391418-84-0 6-(2,6-dichlorobenzyl)-8-({2-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}amino)-2,7-naphthyridin-1(2H)-one 
• 1335053-95-6 1,6-dichloro-2,7-naphthyridine 
• 1263400-43-6 tert-butyl 4-(4-(3-(6-methoxypyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-ylamino)-2-methylphenyl)piperidine-1-carboxylate 
• 1263390-26-6 3-(4-(4-(3-(6-methoxypyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-ylamino)-2-methylphenyl)piperidin-1-yl)propanenitrile 
• 1263400-46-9 tert-butyl 4-(4-(3-(6-methoxypyrazin-2-yl)-8-oxo-7-((2-(trimethylsilyl)ethoxy)methyl)-7,8-dihydro-2,7-naphthyridin-1-ylamino)-2-methylphenyl)piperidine-1-carboxylate 

Relevant articles and documents

TAM KINASE INHIBITORS

Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat diseases, such as cancer.

Inhibiting WNT signal conduction of compound, composition and use thereof (by machine translation)

The invention relates to a having the general formula (1) compounds and compositions thereof, and the use of the compound or composition thereof to inhibit WNT signal transmission method. The compounds of this invention and its composition can effectively inhibit the secretion of WNT protein, inhibit WNT signal conduction, so the WNT-mediated disease with a very good therapeutic effect. . (by machine translation)

TUMOR BIOMARKERS AND USE THEREOF

Disclosed herein are biomarkers related to WNT signal transduction pathway, as well as methods and kits comprising the same. Further, the present disclosure relates to the use of the biomarkers in patient selection, companion diagnostics, and treatment of cancer.